In the present investigation, when sorafenib was combined with fisetin, fisetin potentiated the EMT inhibitory effect of sorafenib and effectively down regulated the expression of Twist1 transcription factor in BRAF-mutated melanoma cells in vitro as well as in xenograft tumors. The gene discussed is TWIST1; the disease is melanoma.